Study guide

10.5 Drug Interactions, Adverse Effects, Pharmacogenomics & Toxicology

APMLE Part I Basic Sciences Podiatry

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview & Lower Extremity Osteology

1.1 APMLE Part I Exam Structure, Policies & Scoring 1.2 Foot Osteology: Tarsals, Metatarsals, Phalanges & Sesamoids 1.3 Leg & Ankle Osteology: Tibia, Fibula & The Ankle Mortise 1.4 Pelvis, Femur & Patella Osteology: Landmarks & Biomechanics

2 Chapter 2: Lower Extremity Arthrology & Ligaments

2.1 Foot Articulations: Subtalar, Midtarsal, Lisfranc & Digital Joints 2.2 Talocrural (Ankle) & Knee Joints: Ligaments & Kinematics 2.3 Hip Joint & Pelvic Articulations: Capsular Structures & Dynamics

3 Chapter 3: Lower Extremity Myology & Compartments

3.1 Anterior & Lateral Compartments of the Leg 3.2 Superficial & Deep Posterior Compartments of the Leg 3.3 Plantar Layers & Intrinsic Musculature of the Foot 3.4 Thigh & Gluteal Musculature: Attachments & Innervations

4 Chapter 4: Lower Extremity Neurovascular & Topographical Anatomy

4.1 Lumbar & Sacral Plexuses, Peripheral Nerves & Dermatomes 4.2 Arterial Network, Venous Drainage & Lymphatics 4.3 Tarsal Tunnel, Femoral Triangle & Topographical Spaces

5 Chapter 5: Microbiology: Bacteriology, Zoonoses & Laboratory Methods

5.1 Gram-Positive Cocci & Bacilli in Podiatric Infections 5.2 Gram-Negative Bacilli & Opportunistic Pathogens 5.3 Anaerobic Pathogens & Diabetic Foot Infections 5.4 Bacterial Structure, Virulence Factors & Sterilization 5.5 Mycobacteria, Spirochetes, Mycoplasma & Zoonotic Infections 5.6 Antimicrobial Resistance, Susceptibility Testing, Specimen Handling & Vaccines

6 Chapter 6: Mycology, Virology, Parasitology & Clinical Immunology

6.1 Mycology: Dermatophytes, Onychomycosis & Systemic Mycoses 6.2 Clinically Relevant Viruses & Parasitic Infections 6.3 Innate & Adaptive Immunity Mechanisms 6.4 Hypersensitivity Reactions, Immunodeficiencies & Autoimmunity 6.5 Transplant & Tumor Immunology and Immunodiagnostic Methods

7 Chapter 7: General & Cellular Pathology

7.1 Cellular Injury, Adaptations & Cell Death Mechanisms 7.2 Acute vs Chronic Inflammation & Tissue Repair 7.3 Hemodynamic Disorders, Thrombosis, Embolism & Shock 7.4 Neoplasia, Oncogenes, Tumor Suppressors & Cutaneous Tumors

8 Chapter 8: Systemic & Podiatric Pathology

8.1 Atherosclerosis, Peripheral Artery Disease & Diabetic Microangiopathy 8.2 Osteoarthritis, Inflammatory Arthritides & Bone Infections 8.3 Neuropathic Disorders, Charcot Neuroarthropathy & Dermatopathology 8.4 Laboratory Diagnostics, Synovial Fluid & Biopsy Interpretation

9 Chapter 9: Organ-System Pathology

9.1 Anemias, Hemoglobinopathies, Leukemias & Immune Disorders 9.2 Cardiac & Pulmonary Pathology 9.3 Renal, Urogenital & Reproductive Pathology 9.4 Gastrointestinal, Hepatobiliary & Endocrine Pathology

10 Chapter 10: General Pharmacology, Autonomic Drugs & Toxicology

10.1 Pharmacokinetics, ADME & Receptor Dynamics 10.2 Cholinergic Agonists & Muscarinic/Nicotinic Antagonists 10.3 Adrenergic Agonists, Sympatholytics & Clinical Applications 10.4 Cardiovascular Pharmacology in Podiatric Patients 10.5 Drug Interactions, Adverse Effects, Pharmacogenomics & Toxicology

11 Chapter 11: Antimicrobial & Podiatric Therapeutics

11.1 Antibacterial Classes, Mechanisms & Resistances 11.2 Antifungal, Antiviral & Antiparasitic Therapeutics 11.3 NSAIDs, Opioids, Corticosteroids & Anti-Gout Agents 11.4 Local & General Anesthetic Pharmacology

12 Chapter 12: Systemic Pharmacology

12.1 Anticonvulsants, Antidepressants, Psychotropics & Skeletal Muscle Relaxants 12.2 Insulin & Noninsulin Glycemic Agents 12.3 Respiratory & Gastrointestinal Agents 12.4 DMARDs, Biologics, Antineoplastics & Immunosuppressants 12.5 Hormone Therapy, Bisphosphonates, Antihistamines, Growth Factors & Complementary Agents

13 Chapter 13: General Anatomy: Systemic Gross Anatomy & Neuroanatomy

13.1 Cranial Nerves, Head & Neck Anatomy 13.2 Thoracic Wall, Tracheobronchial Tree, Lungs & Mediastinum 13.3 Abdominal Wall, GI Viscera, Pelvis & Retroperitoneum 13.4 Vertebral Column, Spinal Cord & Upper Extremity Overview 13.5 Neuroanatomy: CNS Organization, Somatosensory & Motor Pathways

14 Chapter 14: Histology, Integument, Embryology & Genetics

14.1 Microscopic Anatomy: Epithelia, Connective Tissue, Muscle & Nerve 14.2 Integumentary System: Dermis, Appendages, Nail Unit & Cutaneous Receptors 14.3 Embryogenesis, Limb Morphogenesis & Postnatal Development 14.4 Medical Genetics & Structural Alterations in Aging

15 Chapter 15: Cellular, Neuromuscular & Cardiovascular Physiology

15.1 Membrane Potential, Ion Channels & Transport Mechanisms 15.2 Action Potentials, Synaptic Transmission & Muscle Contraction 15.3 Cardiac Electrophysiology, ECG & Hemodynamics 15.4 Blood Pressure Regulation, Poiseuille Law & Capillary Dynamics

16 Chapter 16: Organ-System Physiology: Respiratory, Renal, Endocrine, GI & Blood

16.1 Pulmonary Mechanics, Gas Exchange & Acid-Base Regulation 16.2 Renal Filtration, Tubular Transport & Fluid/Acid-Base Balance 16.3 Endocrine Regulation, Reproductive Hormones, Calcium & Bone 16.4 Gastrointestinal & Hepatobiliary Physiology 16.5 Hematology: Erythropoiesis, Leukocytes, Platelets & Coagulation 16.6 Exercise Physiology, Thermoregulation & Bone Mechanobiology

17 Chapter 17: Biochemistry: Proteins, Enzymes, Carbohydrates & Signaling

17.1 Amino Acid Chemistry, Protein Structure & Enzyme Kinetics 17.2 Glycolysis, Gluconeogenesis, Glycogen Metabolism & TCA Cycle 17.3 Electron Transport Chain, ATP Synthesis & Metabolic Inborn Errors 17.4 Hormones, Receptors, Second Messengers & Signal Transduction

18 Chapter 18: Biochemistry: Lipids, Molecular Genetics, Blood Chemistry & Nutrition

18.1 Fatty Acid Oxidation, Ketogenesis, Cholesterol & Lipoproteins 18.2 Nucleotide Metabolism, DNA Replication, Transcription, Translation & Repair 18.3 Vitamins, Micronutrients & Inborn Errors of Metabolism 18.4 Blood Chemistry: Heme Metabolism, Hemoglobin & Plasma Proteins 18.5 Nutrition: Energy Balance, Glycemic Index, Fed-Fast Cycle & Free Radicals

10.5 Drug Interactions, Adverse Effects, Pharmacogenomics & Toxicology

Key Takeaways Explain This Topic AI

Drug interactions are pharmacokinetic (absorption, CYP450 or P-glycoprotein metabolism, protein binding, renal excretion) or pharmacodynamic (additive, synergistic, potentiating or antagonistic effects at the target).

Grapefruit juice inhibits intestinal CYP3A4, St. John's wort induces CYP3A4 and P-glycoprotein, tyramine-rich foods cause hypertensive crisis with MAO inhibitors, and calcium or iron chelate tetracyclines and fluoroquinolones.

Pharmacogenomic red flags include CYP2D6 ultrarapid codeine metabolism, CYP2C19 loss-of-function with clopidogrel, TPMT or NUDT15 variants with thiopurines, HLA-B 15:02 with carbamazepine, HLA-B 58:01 with allopurinol and G6PD deficiency with oxidant drugs.

Since 2015, FDA prescription labeling describes pregnancy and lactation risk in narrative sections instead of the former A, B, C, D and X letter categories; classic teratogens include warfarin, isotretinoin, valproate, ACE inhibitors, methotrexate and thalidomide.

Key antidotes include N-acetylcysteine for acetaminophen, naloxone for opioids, fomepizole for methanol and ethylene glycol, hydroxocobalamin for cyanide, digoxin immune Fab for digoxin, glucagon for beta-blockers and sodium bicarbonate for tricyclic cardiotoxicity.

Last updated: October 2026

10.5 Drug Interactions, Adverse Effects, Pharmacogenomics & Toxicology

The pharmacology outline lists drug interactions (potentiation, neutralization, genetic factors, drug-drug, supplements and food), adverse effects (allergies, toxicity, specific side effects and teratogenic effects), pharmacogenomics, drug resistance and toxicology. Podiatric patients are often older and take many drugs, so these interactions decide whether a routine antifungal, antibiotic or analgesic is safe.

Classifying Drug Interactions

Type Definition Example

Additive Combined effect equals the sum of the separate effects Two CNS depressants (opioid plus benzodiazepine)

Synergism Combined effect exceeds the sum Beta-lactam plus aminoglycoside against enterococci

Potentiation A drug with little effect of its own enhances another Clavulanate protects amoxicillin from beta-lactamase; probenecid raises penicillin levels

Chemical antagonism (neutralization) Drugs bind each other directly Protamine neutralizes heparin ; chelators bind metals

Pharmacologic antagonism Competition at the same receptor Naloxone displaces opioids

Physiologic antagonism Opposing effects through different receptors Epinephrine reverses histamine-induced bronchospasm

Pharmacokinetic Interactions

Absorption: calcium, magnesium, aluminum and iron chelate tetracyclines and fluoroquinolones ; sucralfate binds fluoroquinolones; itraconazole capsules need gastric acid, so acid suppression lowers absorption.

Distribution: displacement from albumin (sulfonamides displacing warfarin) transiently raises the free drug fraction; it matters most when clearance is also reduced.

Metabolism: CYP450 inducers (rifampin, carbamazepine, phenytoin, St. John's wort) cause therapeutic failure ; inhibitors (azoles, clarithromycin, ritonavir, grapefruit) cause toxicity . The examples in 10.1 and 10.4 (fluconazole-warfarin, itraconazole-atorvastatin) are classics.

Transporters: P-glycoprotein inhibitors (verapamil, clarithromycin, amiodarone) raise digoxin and dabigatran levels.

Excretion: NSAIDs, thiazides and ACE inhibitors reduce lithium clearance; probenecid blocks tubular secretion of penicillins and methotrexate; high-dose NSAIDs and proton pump inhibitors can raise methotrexate levels.

Supplement and Food Interactions

Substance Mechanism Consequence

Grapefruit juice Furanocoumarins irreversibly inhibit intestinal CYP3A4 Higher simvastatin, lovastatin, some calcium channel blockers and cyclosporine

St. John's wort Induces CYP3A4 and P-glycoprotein; serotonergic Lowers cyclosporine, oral contraceptives, warfarin and antiretrovirals; serotonin syndrome with SSRIs

Tyramine (aged cheese, cured meats, tap beer) Not degraded when MAO is inhibited Hypertensive crisis with MAO inhibitors and linezolid

Vitamin K-rich greens Supplies cofactor for clotting factor synthesis Large swings in intake destabilize the INR on warfarin

Ethanol Disulfiram-like reaction; CNS depression; CYP2E1 induction Labeling warns with metronidazole; acetaminophen hepatotoxicity risk

Ginkgo, garlic, fish oil, high-dose vitamin E Antiplatelet effects Bleeding with anticoagulants and around surgery

Pharmacogenomics

Inherited differences in drug-metabolizing enzymes, transporters, targets and HLA alleles explain much variation in response:

Gene or variant Drug Clinical effect

CYP2D6 ultrarapid metabolizer Codeine, tramadol Excess morphine (or O-desmethyltramadol) formation causes respiratory depression; codeine is contraindicated in children younger than 12

  • CYP2C19 poor metabolizer Clopidogrel (prodrug) Reduced activation and more stent thrombosis (boxed warning)
  • CYP2C9 and VKORC1 Warfarin Lower dose requirements and bleeding risk
  • TPMT or NUDT15 deficiency Azathioprine, 6-mercaptopurine Life-threatening myelosuppression

DPYD (DPD deficiency) 5-fluorouracil, capecitabine Severe or fatal toxicity; labeling advises considering DPYD testing

  • HLA-B*15:02 Carbamazepine, phenytoin Stevens-Johnson syndrome and TEN, especially in people of Asian ancestry
  • HLA-B*58:01 Allopurinol Severe cutaneous reactions; testing recommended in high-risk ancestries
  • HLA-B*57:01 Abacavir Hypersensitivity syndrome
  • G6PD deficiency Dapsone, primaquine, rasburicase, sulfonamides, methylene blue Hemolysis
  • NAT2 slow acetylator Isoniazid, hydralazine, procainamide Neuropathy, drug-induced lupus
  • Butyrylcholinesterase variants Succinylcholine Prolonged apnea
  • RYR1 Volatile anesthetics, succinylcholine Malignant hyperthermia
  • Adverse Drug Reactions

Type A (augmented): predictable and dose-related; for example, bleeding with anticoagulants or hypoglycemia with sulfonylureas.

Type B (bizarre): unpredictable and not dose-related; for example, anaphylaxis, SJS/TEN or idiosyncratic hepatotoxicity.

Allergies. About 10% of patients report a penicillin allergy, but most are not truly allergic when tested. Cross-reactivity with cephalosporins depends mainly on R1 side-chain similarity and is low overall. Cefazolin has a unique side chain. Current allergy practice parameters allow most patients with a non-anaphylactic penicillin history to receive a cephalosporin, and many hospitals use cefazolin even after reported anaphylaxis when penicillin skin testing is not available.

Toxicity and specific side effects. These are covered with each drug class: aminoglycoside oto- and nephrotoxicity, fluoroquinolone tendinopathy, NSAID gastropathy and nephropathy, and drug-induced lupus (hydralazine, procainamide, isoniazid, minocycline, TNF inhibitors).

Teratogenic effects. The 2015 Pregnancy and Lactation Labeling Rule replaced the A/B/C/D/X letter categories with narrative risk summaries.

  • Teratogen Effect
  • Warfarin Nasal hypoplasia and stippled epiphyses (warfarin embryopathy)
  • Isotretinoin and high-dose vitamin A Craniofacial, cardiac and CNS defects
  • Valproate, carbamazepine Neural tube defects
  • Phenytoin Fetal hydantoin syndrome (including nail and distal phalangeal hypoplasia)
  • ACE inhibitors and ARBs Renal dysgenesis, oligohydramnios
  • Methotrexate, misoprostol, mycophenolate Fetal loss and malformations
  • Thalidomide Phocomelia (14.3)
  • Tetracyclines Tooth discoloration, bone growth effects
  • Lithium Ebstein anomaly
  • Drug Resistance and Tolerance

Resistance can be microbial (5.6), tumor-related (efflux pumps such as P-glycoprotein and target mutations) or pharmacologic tolerance , meaning a reduced effect after repeated dosing from receptor downregulation or desensitization. Examples include opioid tolerance and tachyphylaxis , a rapid tolerance seen with nitrates and indirect sympathomimetics.

  • Clinical Toxicology
  • Toxidromes

Toxidrome Vital signs Pupils Skin Other

Sympathomimetic (cocaine, amphetamines) High heart rate, blood pressure and temperature Dilated Diaphoretic Agitation, seizures

  • Anticholinergic High heart rate and temperature Dilated Dry, flushed Delirium, urinary retention
  • Cholinergic (organophosphates) Bradycardia Constricted Wet Bronchorrhea, fasciculations (10.2)
  • Opioid Respiratory depression Pinpoint Normal Coma
  • Sedative-hypnotic Normal to low Normal Normal Coma with relatively preserved vital signs
  • Serotonin syndrome High heart rate and temperature Dilated Diaphoretic Clonus and hyperreflexia
  • Antidotes Worth Memorizing
  • Poison Antidote
  • Acetaminophen N-acetylcysteine
  • Opioids Naloxone
  • Benzodiazepines Flumazenil (can provoke seizures in chronic users)
  • Organophosphates Atropine plus pralidoxime
  • Anticholinergic agents Physostigmine (selected cases)
  • Digoxin Digoxin immune Fab
  • Beta-blockers Glucagon
  • Calcium channel blockers IV calcium, high-dose insulin euglycemia therapy
  • Tricyclic antidepressants (wide QRS) Sodium bicarbonate
  • Methanol, ethylene glycol Fomepizole (and hemodialysis)
  • Cyanide Hydroxocobalamin
  • Carbon monoxide 100% oxygen or hyperbaric oxygen
  • Methemoglobinemia Methylene blue (avoid in G6PD deficiency)
  • Iron Deferoxamine
  • Lead Succimer, edetate calcium disodium, dimercaprol
  • Isoniazid seizures Pyridoxine
  • Sulfonylurea hypoglycemia Dextrose plus octreotide
  • Heparin Protamine
  • Warfarin Vitamin K plus 4-factor PCC
  • Dabigatran Idarucizumab
  • Local anesthetic systemic toxicity 20% lipid emulsion (11.4)
  • Malignant hyperthermia Dantrolene

Tip

Before prescribing oral terbinafine, an azole, a fluoroquinolone, a macrolide or an NSAID, reconcile every medication, supplement and food pattern. Most dangerous interactions are predictable from CYP3A4, CYP2C9, CYP1A2, QT and renal-clearance effects.